Komen Breast Cancer Forum

Komen Breast Cancer Forum

Novel Models to Dissect the Immunologic Functions of ADC's

 

Justin M. Balko, Pharm.D., Ph.D.

Ingram Professor for Cancer Research

Professor of Medicine and Pathology, Microbiology and Immunology

Vanderbilt-Ingram Cancer Center

Vanderbilt University Medical Center

 

Wednesday, September 2, 2026 at 9am

Location: NB5.124 Seminar Room (In-person Preferred)

and ZOOM: https://utsouthwestern-edu.zoom.us/j/99013205150?pwd=w5buD9uUD6aGAkKMyMIRmavdjsMyDA.1

Meeting ID: 990 1320 5150       Passcode: 023284

 

About Dr. Balko:

Justin M. Balko, PharmD, PhD is currently an Ingram Associate Professor of Cancer Research and Associate Professor of Medicine and Pathology, Microbiology, and Immunology, and co-leads the VICC Breast Cancer Research Program. He obtained his Doctorate in Pharmacy from the State University of New York at Buffalo in 2004. After completion of his PhD in the Clinical and Experimental Therapeutics track of the Pharmaceutical Sciences program at the University of Kentucky in Lexington, KY, he joined the laboratory of Carlos L. Arteaga, MD, in 2009 as a postdoctoral research fellow.

He has published over 100 peer reviewed contributions in the field of molecular oncology and translational oncology research, primarily in the breast cancer field. His laboratory focuses on identifying biomarkers and mechanisms of drug sensitivity or resistance in breast cancer and other tumor types, ways to enhance response rates to immunotherapy by targeting cancer-specific signals of immune suppression, and the biological mechanisms of immune-related adverse events to immunotherapies. His laboratory receives or has received funding from the NIH/NCI, the Department of Defense, The IBC Network Foundation, the Jimmy V Foundation for Cancer Research, The Mary Kay Foundation, Stand Up 2 Cancer/AACR, and Susan G. Komen.

Research area

Developing methods to identify which patients would benefit from immunotherapy

Impact

Triple-negative breast cancers (TNBCs) lack estrogen and progesterone receptors and the HER2 protein, three factors that are usual targets of therapy. Therefore, it is an aggressive subtype of breast cancer with limited treatment options. Patients with TNBC are typically treated with chemotherapy but, in the last few years, immunotherapy in combination with chemotherapy has achieved some success. Immunotherapy helps a patient’s own immune system fight cancer and can be very effective, but only in about 15 percent of patients with TNBC. The use of immunotherapy drugs is complicated by their potentially life-long side effects including those similar to symptoms of autoimmune disorders. Since many patients would completely respond to chemotherapy alone, these side-effects could be avoided if doctors could select patients most likely to benefit. Dr. Balko and his team are testing a method that may do this through a clinical trial and hope its use will help improve and personalize treatment in a population of patients that currently has limited options.

Progress Thus Far

Dr. Balko and his team have completed trial accrual for the group of patients with early stage TNBC and analyzed tumor tissue samples from over half of these participants. Further, they have accrued over half of the participants with metastatic TNBC needed to meet their goal.

What’s next

Dr. Balko and his team will complete tumor tissue analysis for the group of participants with early stage TNBC. They will also complete enrollment for the metastatic TNBC group and collect and analyze all data associated with those participants. If successful, Dr. Balko hopes to test this technique in larger clinical trials. From the wealth of tumor data they assemble and analyze, the team hopes to identify new effective treatments or biomarkers to improve outcomes for patients with aggressive TNBC.